May. 10 at 9:57 PM
$AIM sentiment is reaching a boiling point after major clinical wins and fresh funding. Ampligen just delivered a 50% ORR, 79% clinical benefit rate, and 32.5-month survival in ovarian cancer with no severe toxicities — a huge validation for the platform. Now the market is watching the upcoming pancreatic cancer Phase 3 setup and June DURIPANC update as potential game-changers.
Bulls see the recent pullback from the
$4.2M warrant exercise as a shakeout before the next move higher. With short interest elevated, momentum building, and biotech eyes locked on the next catalyst, many believe sub-
$1 $AIM could become a major valuation catch-up play if the pancreatic data keeps delivering.
$MRK $TMO $AIM $XBI $IBB
